A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biospecimen Collection.
- Who it may be relevant to
- Registry conditions: Melanoma. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Analysis of the Tumor Microenvironment and Immune Response in Malignant Melanoma
Overview
This study collects and stores blood and tumor samples from patients with malignant melanoma and healthy individuals. The purpose of this study is to gain a better understanding of the causes of melanoma and how melanoma tumors behave. Storing blood and tumor samples for future research may lead to new discoveries that may ultimately help with diagnosing or treating this disease.
Detailed description
PRIMARY OBJECTIVE:
I. Facilitate studies aimed at investigating new prognostic markers and potentially therapeutic therapies in malignant melanoma.
OUTLINE:
Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year.
Interventions
- Procedure Biospecimen Collection
Undergo collection of blood and tissue samples
Primary outcome measures
- New prognostic markers in malignant melanoma [Time frame: Up to 3 months]
Eligibility criteria
Inclusion criteria
- Patient with malignant melanoma or personal history of melanoma
- Normal donors
- Informed consent can be obtained
- Patients with any stage of malignant melanoma
Exclusion criteria
- Incarcerated individuals will be excluded from this protocol
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Ohio State University Comprehensive Cancer Center — Columbus
Identifiers
NCT: NCT04567706 · OSU-13114 · NCI-2020-06536